Skip to search formSkip to main contentSkip to account menu

Anti-FGFR2 Antibody-drug Conjugate BAY1187982

Known as: ADC BAY1187982, BAY 1187982, BAY1187982 
An antibody-drug conjugate (ADC) directed against the fibroblast growth factor receptor type 2 (FGFR2) and conjugated to an as of yet unidentified… 
National Institutes of Health

Related topics

Related topics

1 relation
Receptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Downregulating oncogenic receptor: From bench to clinic
In 1989-1991, George Zhu first postulate oncogenic receptor (Voice of America,1992,12:31;Curr Pharm Biotechnol,2013,14:859-863… 
2015
2015
Abstract 1684: Preclinical anti-tumor efficacy of FGFR2-ADC BAY 1187982 in patient-derived gastric, breast and ovarian cancer models
Antibody-drug conjugates (ADC) represent a promising therapeutic approach for treatment of cancer. We have developed a novel ADC… 
2015
2015
Abstract 1683: Pharmacokinetic/pharmacodynamic (PK/PD) and toxicokinetic/toxicodynamic (TK/TD) modeling of preclinical data of FGFR2-ADC (BAY 1187982) to guide dosing in phase 1
Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA BAY 1187982 is an antibody drug conjugate (ADC… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)